EX-99.1 2 q32016-ex991earningsrelease.htm EXHIBIT 99.1 Exhibit


FOR RELEASE ON: November 9, 2016 at 1601 ET

Exhibit 99.1

CONTACT: Arvind Bobra
Investor Relations
TASER International, Inc.
IR@taser.com

TASER Reports 2016 Third Quarter Results
Record Revenues of $71.9 million, Up 43% Year-Over-Year
Company Announces CFO Transition Plan
Axon Bookings Grew 56% to $57.5 Million


SCOTTSDALE, Ariz., November 9, 2016 − TASER International, Inc. (Nasdaq: TASR), today reported financial results for the third quarter ended September 30, 2016.

“I am simply delighted with the results of our team's extraordinary work this part quarter. We realized strong growth in the period from both our Weapons and Axon businesses, and our Axon bookings remained strong,” commented Rick Smith, TASER CEO and Founder. “Customers value the Axon network we have created, which now connects over half of the major cities in the United States, bringing the criminal justice system online with advanced technology and enhanced transparency. We will continue to grow our existing platform offerings while developing complementary capabilities to extend our leadership position with law enforcement around the world.”

Third Quarter 2016 Financial Highlights:

•
Net sales increased 43% to $71.9 million in the third quarter of 2016 compared to $50.4 million in the third quarter of 2015. International sales were $11.3 million in the third quarter of 2016.

•
TASER Weapons segment revenues increased 34% to $52.9 million in the third quarter of 2016 compared to $39.5 million in the third quarter of 2015.

•
Axon segment revenues increased 75% to $18.9 million in the third quarter of 2016 compared to $10.9 million in the third quarter of 2015.

•
Consolidated gross margin was 65% in the third quarter of 2016 compared to 62% in the third quarter of 2015.

•
TASER Weapons segment gross margin was 72% in third quarter 2016 compared to 69% in the third quarter of 2015.





•
Axon segment gross margins increased to 45% in the third quarter of 2016 compared to 37% in the third quarter of 2015. Axon service margins increased to 81% in the third quarter of 2016 compared to 67% in the third quarter of 2015. Axon hardware product margins (excluding Axon services) decreased to 15% in the third quarter 2016 compared to 25% in the third quarter of 2015.

•
Sales, general and administrative (SG&A) expenses of $28.1 million in the third quarter of 2016 increased $10.3 million, from $17.8 million in the third quarter of 2015. The increase is primarily due to increased headcount, expenses related to international expansion, professional/consulting fees, legal costs, and higher variable compensation.

•
Research and development (R&D) expenses of $7.4 million for the third quarter of 2016 increased $0.8 million when compared to the third quarter of 2015. The increase is primarily related to increased headcount.

•
Income from operations was $11.1 million in the third quarter of 2016 compared to $6.7 million in the third quarter of 2015.

•
Income tax expense in the quarter was $6.8 million for an effective tax rate of 63.9%.  We were adversely affected by losses in foreign entities from which we do not currently expect to receive a tax benefit.  Additionally, we recognized an unfavorable provision to tax return true up relating to our 2015 tax return filed in September of $0.4 million. The combined impact of the foreign entity losses which we do not currently expect to receive a tax benefit from and the return to provision true up is approximately $1.5 million or $0.03 cents per share.

•
Net income for the third quarter of 2016 was $3.8 million, or $0.07 per diluted share, compared to $1.5 million, or $0.03 per diluted share, in the third quarter of 2015.

•
Adjusted EBITDA for the third quarter of 2016 was $13.8 million compared to $9.5 million in the third quarter of 2015.

•
In the third quarter of 2016, the Company generated $11.6 million in cash from operating activities. Cash, cash equivalents and investments were $102.5 million at September 30, 2016, compared to $118.3 million at December 31, 2015. Included in these balances were $6.3 million and $8.5 million in long-term investments as of September 30, 2016 and December 31, 2015, respectively.

Business Highlights:

•
As of the end of the third quarter of 2016, 35 of the 68 U.S. major city law enforcement agencies have purchased TASER's Axon body-worn cameras and/or its digital evidence management solution: Albuquerque, Atlanta, Baltimore, Baltimore County, Charlotte-Mecklenburg, Chicago, Cincinnati, Cleveland, Dallas, Denver, Fort Worth, Fresno, Kansas




City, Los Angeles, Las Vegas, Louisville, Memphis, Mesa, Miami, Milwaukee, Minneapolis, Montgomery County, New Orleans, Omaha, Philadelphia, Pittsburgh, Salt Lake City, San Antonio, San Diego, San Francisco, San Jose, Tampa, Tucson, Washington, DC, and Wichita.

•
Axon platform user count continued to grow, extending the Company's market leadership. During the three months ended September 30, 2016, the Company booked approximately 15,600 seats on its digital evidence management platform, Evidence.com, net of renewals. Since inception, the Company has booked cumulative Evidence.com licenses of approximately 110,600.

CFO Transition

TASER also announced today that following a transition period, CFO Dan Behrendt will be leaving the Company to pursue other opportunities. Mr. Behrendt will remain with TASER in his current capacity through the filing of the Company’s Form 10-K to help ensure an orderly transition of his responsibilities. The Company has commenced a national search for a new Chief Financial Officer.
“Dan has been an integral part of TASER’s success since joining 12 years ago,” said Mr. Smith. “He has brought strong financial leadership to the organization, most notably as we’ve broadened our law enforcement solutions capabilities to include our Axon-branded, cloud-connected device platform. We thank Dan for his many contributions to TASER during his tenure and for the positive impact he has had on our organization.”

Mr. Behrendt commented, “I am grateful for the opportunity to serve as part of the leadership team at TASER, and I am confident that we have built a solid foundation for future growth. We’ve made considerable progress over the last several years, and I’m particularly proud of the finance organization and team we’ve put in place. After more than a decade with TASER and following an orderly transition period, I’ll look forward to pursuing new endeavors.”

Quarterly Conference Call:

The Company will host its third quarter 2016 earnings conference call on Wednesday, November 9, 2016 at 4:30 p.m. ET. To join the live audio presentation, please dial toll free 877-303-9126, or for international callers, please dial +1-253-237-1156. The passcode is 56350705.

The Company has posted supplemental materials including its key operating metrics on its website to provide additional information about our third quarter financial results.

The Company plans to update and post its investor relations presentation to http://investor.taser.com within the next two weeks with the third quarter results. Archived presentations from previous quarters can also be found on the website.

Statistical Definitions:

•
Axon cameras and Evidence.com bookings represent a statistical measure defined as the




sales price of orders placed in the relevant time period. Bookings are an indication of the activity the Company is seeing relative to Axon cameras and Evidence.com. We consider bookings to be a statistical measure defined as the sales price of orders (not invoiced sales) placed in the relevant fiscal period, net of cancellations, regardless of when the products or services ultimately will be provided. Some bookings might be invoiced in subsequent years.

Due to municipal government funding rules, certain of the future year amounts included in bookings are subject to budget appropriation or other contract cancellation clauses. Although TASER has entered into contracts for the delivery of products and services in the future and anticipates the contracts will be completed, if agencies invoke a cancellation clause or do not appropriate funds in future year budgets, revenue associated with these bookings will ultimately not be recognized, resulting in a future reduction to bookings. In the third quarter of 2016, there was approximately $107,000 in reversals related to prior period bookings due to non-appropriation or other cancellation reasons.

For more information relative to our revenue recognition policies, please reference our SEC filings.

Non-GAAP Measures:

To supplement the Company’s financial results presented in accordance with GAAP, we present the non-GAAP financial measures of EBITDA, Adjusted EBITDA and Free Cash Flow. Our management uses these non-GAAP financial measures in evaluating the Company’s performance in comparison to prior periods. We believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance, and when planning and forecasting our future periods. A reconciliation of GAAP to the non-GAAP financial measures is presented at the end of the release.

EBITDA is defined as consolidated net income before interest expense, income taxes and depreciation and amortization. Adjusted EBITDA, as presented herein, is defined as EBITDA before certain other items, including: stock-based compensation; net gain/loss on write-down/disposal of property, equipment and intangible assets; and loss on impairment.

Free Cash Flow is defined as cash flows provided by operating activities minus purchases of property, plant and equipment and intangible assets.

Caution on Use of Non-GAAP Measures

Although these non-GAAP financial measures are not consistent with GAAP, management believes investors will benefit by referring to these non-GAAP financial measures when assessing the Company’s operating results, as well as when forecasting and analyzing future periods. However, management recognizes that:

•
these non-GAAP financial measures are limited in their usefulness and should be considered only as a supplement to the Company’s GAAP financial measures;




•
these non-GAAP financial measures should not be considered in isolation from, or as a substitute for, the Company’s GAAP financial measures;
•
these non-GAAP financial measures should not be considered to be superior to the Company’s GAAP financial measures; and
•
these non-GAAP financial measures were not prepared in accordance with GAAP and investors should not assume that the non-GAAP financial measures presented in this earnings release were prepared under a comprehensive set of rules or principles.

Further, these non-GAAP financial measures may be unique to the Company, as they may be different from similarly titled non-GAAP financial measures used by other companies. As such, this presentation of non-GAAP financial measures may not enhance the comparability of the Company’s results to the results of other companies.

About TASER International, Inc.

TASER International makes communities safer with innovative public safety technologies. Founded in 1993, TASER first transformed law enforcement with its electrical weapons. TASER continues to define smarter policing with its growing suite of technology solutions, including Axon body-worn video cameras and Evidence.com, a secure digital evidence management platform. More than 174,000 lives saved from death or serious injury and countless dollars have been saved with TASER's products and services.

Learn more at www.taser.com and www.axion.io or by calling (800) 978-2737.

TASER® and Axon® are registered trademark of TASER International, Inc., registered in the U.S. All rights reserved. TASER logo, Axon, Axon Body, Axon Body 2, Axon Flex, Axon Interview, Axon Signal, TASER X26, TASER X26P, TASER CAM and TASER X2 are trademarks of TASER International, Inc. All rights are reserved for trademarks of TASER International, Inc.

Note to Investors

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including statements regarding our expectations, beliefs, intentions or strategies regarding the future. We intend that such forward-looking statements be subject to the safe-harbor provided by the Private Securities Litigation Reform Act of 1995. The forward-looking information is based upon current information and expectations regarding TASER International, Inc. These estimates and statements speak only as of the date on which they are made, are not guarantees of future performance, and involve certain risks, uncertainties and assumptions that are difficult to predict. TASER International assumes no obligation to update the information contained in this press release, except as required by law.

We caution that these statements are qualified by important factors that could cause actual results to differ materially from those reflected by the forward looking statements herein. Such factors




include, but are not limited to: the adverse effect of the United Kingdom's exit from the European Union; market acceptance of our products; our dependence on sales of our TASER X26P and X2 CEWs; our ability to design, introduce and sell new products; delays in development schedules; rapid technological change and competition; product defects; breach of our security measures resulting in unauthorized access to customer data; outages and disruptions relating to our Evidence.com service; budgetary and political constraints of prospects and customers; the length of our sales cycle and our ability to realize benefits from our marketing and selling efforts; our exposure to cancellations of government contracts due to appropriation clauses; changes in civil forfeiture laws; the long-term revenue recognition cycle for our SaaS Evidence.com product; our reliance on third party cloud-based storage providers; litigation risks resulting from alleged product-related injuries and media publicity concerning allegations of deaths occurring after use of the TASER device and the negative impact this publicity could have on sales; the outcome of pending or future litigation; our ability to protect our intellectual property as well as intellectual property infringement claims and relating litigation costs; our successful identification of existing intellectual property rights that might infringe on our developments; competition in foreign countries relating to our inability to protect our patents; risks of governmental regulations, including regulations of our products by the United States Consumer Product Safety Commission, regulation of our products as a "crime control" product by the Federal government, state and local government regulation and foreign regulation and the adverse effects that could result from our products being classified as firearms by the United States Bureau of Alcohol and Firearms; regulatory and political challenges presented by international markets; our compliance with regulations governing the environment, including but not limited to, regulations within the European Union; regulations relating to voice, data and communications services; regulations relating to conflict minerals;  our dependence on third party suppliers for key components of our products; component shortages; rising costs of raw materials and transportation relating to petroleum prices; that we may experience declines in gross margins due to a shift in product sales from conducted electrical weapons to Axon devices; our ability to manage our growth and increase manufacturing production to meet demand; establishment and expansion of our direct and indirect distribution channels; our ability to pursue sales directly with customers; risks relating to acquisitions and joint ventures; goodwill impairment; catastrophic events; quarterly fluctuations in our operating results; the adverse effects on our operations and financial results from foreign currency fluctuations; fluctuations in our effective tax rate; counter-party risks relating to cash balances held in excess of FDIC insurance limits; employee retention risks; volatility in our stock price; and other factors identified in documents filed by us with the Securities and Exchange Commission, including those set forth in our Form 10-K for the year ended December 31, 2015 and Forms 10-Q for the quarters ended March 31, 2016 and June 30, 2016.

Please visit http://investor.taser.com, www.twitter.com/officialtaser, www.twitter.com/axontechnology and www.facebook.com/TASER.International where TASER discloses information from time to time about the company, its financial information, and its business.

For investor relations information please contact Arvind Bobra via email at IR@taser.com.

- More -





TASER INTERNATIONAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(in thousands, except per share data)

 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
 
 
 
 
 
 
 
 
Net sales
$
71,882

 
$
50,376

 
$
186,168

 
$
141,851

Cost of products sold and services delivered
25,317

 
19,308

 
65,402

 
50,192

Gross margin
46,565

 
31,068

 
120,766

 
91,659

Operating expenses:
 
 
 
 
 
 
 
Sales, general and administrative
28,121

 
17,834

 
77,333

 
47,842

Research and development
7,358

 
6,528

 
20,995

 
16,992

Total operating expenses
35,479

 
24,362

 
98,328

 
64,834

Income from operations
11,086

 
6,706

 
22,438

 
26,825

Interest income and other (expense) income, net
(455
)
 
(22
)
 
(460
)
 
12

Income before provision for income taxes
10,631

 
6,684

 
21,978

 
26,837

Provision for income taxes
6,788

 
5,163

 
11,022

 
12,008

Net income
$
3,843

 
$
1,521

 
$
10,956

 
$
14,829

Net income per common and common equivalent shares:
 
 
 
 
 
 
 
Basic
$
0.07

 
$
0.03

 
$
0.21

 
$
0.28

Diluted
$
0.07

 
$
0.03

 
$
0.20

 
$
0.27

Weighted average number of common and common equivalent shares outstanding:
 
 
 
 
 
 
 
Basic
52,206

 
53,709

 
52,791

 
53,509

Diluted
53,141

 
54,691

 
53,656

 
54,671






TASER INTERNATIONAL, INC.
SEGMENT REPORTING
(Unaudited)
(dollars in thousands)

 
Three Months Ended September 30, 2016
 
Three Months Ended September 30, 2015
 
TASER
Weapons
 
Axon
 
Total
 
TASER
Weapons
 
Axon
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
Product sales
$
52,938

 
$
10,266

 
$
63,204

 
$
39,520

 
$
7,745

 
$
47,265

Service revenue
—

 
8,678

 
8,678

 
—

 
3,111

 
3,111

Net sales
52,938

 
18,944

 
71,882

 
39,520

 
10,856

 
50,376

Cost of products sold
14,973

 
8,691

 
23,664

 
12,445

 
5,829

 
18,274

Cost of services delivered
—

 
1,653

 
1,653

 
—

 
1,034

 
1,034

Gross margin
37,965

 
8,600

 
46,565

 
27,075

 
3,993

 
31,068

Sales, general and administrative
16,439

 
11,682

 
28,121

 
11,941

 
5,893

 
17,834

Research and development
1,408

 
5,950

 
7,358

 
1,151

 
5,377

 
6,528

Income (loss) from operations
$
20,118

 
$
(9,032
)
 
$
11,086

 
$
13,983

 
$
(7,277
)
 
$
6,706

 
 
 
 
 
 
 
 
 
 
 
 
Gross margin %
71.7
%
 
45.4
 %
 
64.8
%
 
68.5
%
 
36.8
 %
 
61.7
%
Operating margin %
38.0
%
 
(47.7
)%
 
15.4
%
 
35.4
%
 
(67.0
)%
 
13.3
%

 
Nine Months Ended September 30, 2016
 
Nine Months Ended September 30, 2015
 
TASER
Weapons
 
Axon
 
Total
 
TASER
Weapons
 
Axon
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
Product sales
$
144,307

 
$
23,438

 
$
167,745

 
$
115,686

 
$
18,177

 
$
133,863

Service revenue
—

 
18,423

 
18,423

 
—

 
7,988

 
7,988

Net sales
144,307

 
41,861

 
186,168

 
115,686

 
26,165

 
141,851

Cost of products sold
43,998

 
17,174

 
61,172

 
34,805

 
12,692

 
47,497

Cost of services delivered
—

 
4,230

 
4,230

 
—

 
2,695

 
2,695

Gross margin
100,309

 
20,457

 
120,766

 
80,881

 
10,778

 
91,659

Sales, general and administrative
46,395

 
30,938

 
77,333

 
33,469

 
14,373

 
47,842

Research and development
3,773

 
17,222

 
20,995

 
3,418

 
13,574

 
16,992

Income (loss) from operations
$
50,141

 
$
(27,703
)
 
$
22,438

 
$
43,994

 
$
(17,169
)
 
$
26,825

 
 
 
 
 
 
 
 
 
 
 
 
Gross margin %
69.5
%
 
48.9
 %
 
64.9
%
 
69.9
%
 
41.2
 %
 
64.6
%
Operating margin %
34.7
%
 
(66.2
)%
 
12.1
%
 
38.0
%
 
(65.6
)%
 
18.9
%





TASER INTERNATIONAL, INC.
Axon and Evidence.com Bookings by Quarter
(Unaudited)
(in thousands)

 
September 30, 2016
 
June 30, 2016
 
March 31, 2016
 
December 31, 2015
 
September 30, 2015
 
 
 
 
 
 
 
 
 
 
Bookings
$
57,491

 
$
72,034

 
$
52,059

 
$
44,668

 
$
36,877






Axon and Evidence.com Future Contracted Revenue
(Unaudited)
(in thousands)

 
September 30, 2016
 
June 30, 2016
Cumulative bookings, net of cancellations
$
392,070

 
$
334,579

Cumulative Axon & Evidence.com recognized revenue
(90,047
)
 
(71,799
)
Future contracted revenue
$
302,023

 
$
262,780


Axon and Evidence.com future contracted revenue represent a statistical measure defined as cumulative bookings for Axon and Evidence.com minus cumulative recognized revenue related solely to Axon and Evidence.com. Future contracted revenues are an indication of momentum of longer-term contracts being signed and the expectations of future revenues in the Axon segment. Cumulative Axon & Evidence.com recognized revenue is presented as the Axon segment revenues exclusive of TASER Cam recorder revenues.






TASER INTERNATIONAL, INC.
UNIT SALES STATISTICS
(Unaudited)
Units in whole number

 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
Unit Change
 
Percent Change
 
2016
 
2015
 
Unit Change
 
Percent Change
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TASER X26P
23,259

 
13,659

 
9,600

 
70.3
 %
 
58,385

 
45,946

 
12,439

 
27.1
 %
TASER X2
12,481

 
8,036

 
4,445

 
55.3

 
34,697

 
25,510

 
9,187

 
36.0

TASER X26
365

 
818

 
(453
)
 
(55.4
)
 
1,886

 
4,341

 
(2,455
)
 
(56.6
)
TASER Pulse and Bolt
1,936

 
1,801

 
135

 
7.5

 
6,522

 
5,785

 
737

 
12.7

Cartridges
544,671

 
435,237

 
109,434

 
25.1

 
1,424,656

 
1,189,118

 
235,538

 
19.8

Axon Flex
4,961

 
6,759

 
(1,798
)
 
(26.6
)
 
11,026

 
15,921

 
(4,895
)
 
(30.7
)
Axon Body
25,093

 
4,778

 
20,315

 
425.2

 
40,977

 
15,381

 
25,596

 
166.4

E-Dock
6,432

 
2,075

 
4,357

 
210.0

 
11,236

 
5,554

 
5,682

 
102.3

TASER Cam
1,323

 
2,887

 
(1,564
)
 
(54.2
)
 
6,460

 
8,993

 
(2,533
)
 
(28.2
)







TASER INTERNATIONAL, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(Unaudited)
Dollars in thousands

 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
 
 
 
 
 
 
 
 
Net income
$
3,843

 
$
1,521

 
$
10,956

 
$
14,829

   Depreciation and amortization
901

 
948

 
2,744

 
2,310

   Interest expense, net
—

 
8

 
10

 
9

   Provision for income taxes
6,788

 
5,163

 
11,022

 
12,008

EBITDA
$
11,532

 
$
7,640

 
$
24,732

 
$
29,156

 
 
 
 
 
 
 
 
Adjustments:
 
 
 
 
 
 
 
Stock-based compensation expense
$
2,216

 
$
1,863

 
$
6,742

 
$
5,086

Net loss on disposal of property, equipment and intangible assets, net
64

 
38

 
61

 
203

Adjusted EBITDA
$
13,812

 
$
9,541

 
$
31,535

 
$
34,445

Adjusted EBITDA as a percentage of net sales
19.2
%
 
18.9
%
 
16.9
%
 
24.3
%
 
 
 
 
 
 
 
 
Composition of stock-based compensation:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
 
 
 
 
 
 
 
 
Cost of products sold and services delivered
$
77

 
$
118

 
$
247

 
$
276

Sales, general and administrative
1,348

 
1,123

 
4,197

 
2,982

Research and development
791

 
622

 
2,298

 
1,828

 
$
2,216

 
$
1,863

 
$
6,742

 
$
5,086





TASER INTERNATIONAL, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
 
September 30, 2016
 
December 31, 2015
 
(Unaudited)
 
 
ASSETS
Current Assets:
 
 
 
Cash and cash equivalents
$
50,600

 
$
59,526

Short-term investments
45,620

 
50,254

Accounts and notes receivable, net
32,858

 
27,701

Inventory, net
25,503

 
15,763

Prepaid expenses and other current assets
13,867

 
8,165

Total current assets
168,448

 
161,409

 
 
 
 
Property and equipment, net
22,976

 
21,848

Deferred income tax assets, net
16,753

 
13,719

Intangible assets, net
7,116

 
7,588

Goodwill
8,885

 
9,596

Long-term investments
6,260

 
8,525

Other assets
21,762

 
7,196

Total assets
$
252,200

 
$
229,881

 
 
 
 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
 
 
 
Accounts payable
$
8,982

 
$
7,333

Accrued liabilities
16,086

 
8,643

Current portion of deferred revenue
41,284

 
20,851

Customer deposits
1,367

 
1,226

Current portion of debt and capital lease payable
51

 
87

Total current liabilities
67,770

 
38,140

 
 
 
 
Deferred revenue, net of current portion
35,968

 
30,190

Liability for unrecognized tax benefits
1,332

 
1,315

Long-term deferred compensation
3,111

 
2,199

Long-term contingent consideration
—

 
952

Other long-term liabilities
2,691

 
81

Total liabilities
110,872

 
72,877

 
 
 
 
Stockholders’ Equity:
 
 
 
Preferred stock
—

 
—

Common stock
1

 
1

Additional paid-in capital
184,937

 
178,143

Treasury stock
(155,947
)
 
(122,201
)
Retained earnings
111,934

 
100,978

Accumulated other comprehensive income
403

 
83

Total stockholders’ equity
141,328

 
157,004

Total liabilities and stockholders’ equity
$
252,200

 
$
229,881






TASER INTERNATIONAL, INC.
SELECTED CASH FLOW INFORMATION
(Unaudited)
(in thousands)

 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
 
 
 
 
 
 
 
 
Net income
$
3,843

 
$
1,521

 
$
10,956

 
$
14,829

Depreciation and amortization
901

 
948

 
2,744

 
2,310

Stock-based compensation
2,216

 
1,863

 
6,742

 
5,086

Net cash provided by operating activities
11,623

 
19,345

 
21,959

 
30,314

Net cash provided by (used in) investing activities
639

 
(6,097
)
 
2,285

 
(33,293
)
Net cash provided by (used in) financing activities
719

 
(7,704
)
 
(33,801
)
 
429

Cash and cash equivalents, end of period
50,600

 
45,887

 
50,600

 
45,887

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
 
 
 
 
 
 
 
 
Net cash provided by operating activities
$
11,623

 
$
19,345

 
$
21,959

 
$
30,314

Purchases of property and equipment
(1,371
)
 
(2,069
)
 
(3,335
)
 
(3,839
)
Purchases of intangible assets
(154
)
 
(201
)
 
(339
)
 
(402
)
Purchase of property and equipment and intangible assets in connection with business acquisition
—

 
(3,005
)
 
—

 
(12,804
)
Free cash flow, a non-GAAP measure
$
10,098

 
$
14,070

 
$
18,285

 
$
13,269



# # #